(Q37183932)

18 August 2017

1 reference

title

Current management of the cognitive dysfunction in Parkinson's disease: how far have we come? (English)

1 reference

18 August 2017

1 reference

cognitive dysfunction

1 reference

Salvador Vale

1

1 reference

PubMed ID

18535172

18 August 2017

language of work or name

English

0 references

publication date

5 June 2008

1 reference

Experimental Biology and Medicine

18 August 2017

1 reference

18 August 2017

233

1 reference

18 August 2017

8

1 reference

18 August 2017

941-951

1 reference

A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment.

18 August 2017

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Mortality in Parkinson's disease and its association with dementia and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Relationship between Parkinson disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Different species of alpha-synuclein oligomers induce calcium influx and seeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Action and object naming in Parkinson's disease without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Tolcapone improves cognition and cortical information processing in normal human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Pharmacologic treatment expectations in the management of dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Pharmacological aspects of (-)-deprenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Selegiline can mediate neuronal rescue rather than neuronal protection

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

In vitro galantamine-memantine co-application: mechanism of beneficial action.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Acceleration of amyloid beta-peptide aggregation by physiological concentrations of calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET).

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Association between amantadine and the onset of dementia in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Possible use of amantadine in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Low dose aspirin and cognitive function in the women's health study cognitive cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Ageing and early-stage Parkinson's disease affect separable neural mechanisms of mesolimbic reward processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Dopaminergic modulation of cortical function in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors elicits neuroprotection after trimethyltin exposure in hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

AMPA receptor potentiators: application for depression and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Population-based case-control study of cognitive function in essential tremor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Concise review: therapeutic strategies for Parkinson disease based on the modulation of adult neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Dopamine depletion impairs precursor cell proliferation in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Immortalized multipotential mesenchymal cells and the hematopoietic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Marrow stromal cells, mitosis, and neuronal differentiation: stem cell and precursor functions

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Molecular targets for treating cognitive dysfunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

The progression of Parkinson disease: a hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

How migraines impact cognitive function: findings from the Baltimore ECA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Advances in understanding ventromedial prefrontal function: the accountant joins the executive

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

Frontal mysteries revealed.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0707-MR-193

21 January 2018

Identifiers

DOI

10.3181/0707-MR-193

1 reference

18 August 2017

1 reference

PubMed ID

18535172